DSM announces JV with Nenter to produce Vitamin E

Royal DSM intends to create a 75/25 joint venture with Nenter & Co., Inc., which will include all Nenter’s production and related assets for Vitamin E.

In order to fulfill its future need for Vitamin E, DSM will acquire a 75% shareholding in the joint venture, for a cash consideration of about € 135 million, representing an EV/EBITDA multiple of roughly 6x based on the estimated 2019 EBITDA generated by Nenter’s Vitamin E business.

The joint venture will acquire and operate the Vitamin E production facilities in Jingzhou, Hubei, China and have a minority shareholding in Nenter’s Shishou facility, also in Hubei, China. The joint venture will exclusively produce Vitamin E for DSM subject to existing supply agreements of Nenter, and there will be a profit share agreement in place between DSM and Nenter.

DSM will, together with the joint venture partner Nenter, upgrade and refurbish the facilities and improve the operational performance, to secure high-quality and sustainable supply of Vitamin E, while ensuring compliance with DSM’s safety, health and sustainability standards.

The transaction is subject to several regulatory approvals and expected to close in Q2/Q3 2019. As of the date of gaining control DSM will consolidate the entity.